Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to identify clinical and genetic markers of ovarian aging. In this process, we will evaluate environmental factors that may affect fertility and the age at which fertility declines, and may influence the age at which women enter menopause. Wide variability exists between women both in the age at which menopause occurs and the rate of decline in oocyte number and reproductive capability. As the loss of ovarian function has profound impact on women's hormonal milieu and their subsequent risk for the development of disease, improving our understanding of the factors that determine the timing and rate of reproductive aging is critical to improving quality of life for all women. In addition, improving our understanding of reproductive aging has profound economic, and social, implications given the complex choices women face regarding the timing of childbearing and the growing burden of infertility. While the inter-individual variability in age at menopause has a large genetic component and possible environmental influences, to date no studies have addressed the relationship between oocyte number as reflected by antral follicle count (AFC) and genetic inheritance. We hypothesize that ovarian aging, as reflected by antral follicle count, is largely determined by common genetic polymorphisms that impact the initial oocyte endowment and/or the rate of oocyte loss over time thus lowering antral follicle count for any given age. We further hypothesize that antral follicle count will be an improved marker of ovarian aging. Thus, we propose a study of the genetic and environmental factors that influence age-specific variability in antral follicle count.


Clinical Trial Description

This is a cross-sectional study with a subgroup followed longitudinally over time. This study consists of four basic components: - identification and recruitment of a population-based sample of 1,250 regularly cycling women of diverse ethnicities, ages 25-45; - a baseline examination on days 2-4 of the menstrual cycle, including a blood draw, transvaginal ultrasound examination, body size measurements, and questionnaires, to establish cross-sectional relations between the AFC and the genetic and environmental exposures of interest (see Specific Aims); - genetic analyses of X-chromosome and autosomal mutations, deletions, and polymorphisms, implicated in the control of ovarian function; and - follow-up examination, 3 years after baseline, completed by approximately one-third of the cohort (n=450), to begin to describe longitudinal relations between AFC and the exposures of interest and to identify markers predictive of accelerated follicle loss. Specific Aims: 1. Characterize antral follicle count (AFC) as a marker of ovarian age by comparing it to other available biomarkers, Follicle Stimulating Hormone (FSH), FSH/Lutenizing Hormone (LH), and inhibin B, and determine effect modification of these relationships by age. 2. Examine the relationship between antral follicle counts and the frequencies of specific genetic polymorphisms in the Deleted in AZoospermia-Like (DAZL) and interacting protein genes. 3. Determine the associations between race/ethnicity, body fat, and active and passive smoking and AFC, independently of age; if main effects are observed between genetic polymorphisms and AFC (Specific Aim 2), explore the effect modification of those relationships by race/ethnicity, body fat and active and passive smoking. 4. Determine the change in AFC over a three-year period and its relation to genetic and environmental characteristics, based on the approximately 450 women who complete a 3-year follow-up examination. The primary goal of this study is to demonstrate the relationship between antral follicle count and common genetic polymorphisms and the effect of modification of environmental factors. To achieve this goal, our multidisciplinary team proposes to recruit a random sample of 1,250 regularly cycling, ethnically diverse women, ages 25-45, who belong to the Northern California Kaiser Permanente Medical Care (KPMC) Program in San Francisco. This study will provide evidence to support ultrasound evaluation as a non-invasive marker of ovarian aging. This and the genetic testing may lead to an opportunity for prospective identification of patients at risk for early decline in ovarian function. The ability to accurately generate and share this type of information will allow women to become proactive in managing their fertility as well as to better understand their risks associated with reproductive aging. The recruitment of a large, population-based cohort will increase the generalizability of the data generated. The ethnic diversity of this population will allow multiple comparisons to identify true "risk factors" for early, and/or accelerated, ovarian aging and their correlation with ethnicity. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00501800
Study type Observational
Source University of California, San Francisco
Contact
Status Active, not recruiting
Phase
Start date November 2006
Completion date July 2025

See also
  Status Clinical Trial Phase
Completed NCT03607409 - Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
Recruiting NCT02312076 - GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles Phase 4
Terminated NCT02161861 - Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study N/A
Completed NCT03287479 - Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®) N/A
Terminated NCT03522350 - Randomized Trial Comparing EmbryoScope With EmbryoScope+. N/A
Completed NCT04496284 - Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen N/A
Completed NCT03623659 - pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts N/A
Completed NCT03895099 - New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors Phase 3
Active, not recruiting NCT04142112 - Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation N/A
Completed NCT03152643 - Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer N/A
Recruiting NCT03683771 - Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
Recruiting NCT03161119 - Comparing Two Different Embryo Transfer Catheters N/A
Completed NCT04108039 - Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles. N/A
Completed NCT03677492 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD) N/A
Completed NCT03678584 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA) N/A
Completed NCT03678818 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA) N/A
Completed NCT03678610 - Handling Medium for ICSI With Ionomycin and Latrunculin A N/A
Completed NCT03678571 - Oocyte Vitrification Aided With Latrunculin A N/A
Completed NCT03678558 - Oocyte Vitrification Aided With Cytochalasin B N/A
Completed NCT03678597 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB) N/A